A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-23

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled first-in-human, Phase 1, safety, tolerability, pharmacokinetic (PK) and preliminary exploratory activity study of escalating multiple intravenous (IV) doses of IBC-Ab002 in persons with early Alzheimer's disease. The study will have both Single- and Multiple-Ascending Dose components.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects in 5 sequential cohorts of 8 subjects each will be assigned in a 3:1 ratio to receive either IBC-Ab002 or matching placebo 4 times. Part A will be a single-ascending dose study and Part B will be a multiple ascending dose study. The two parts of the study will be intercalated such that subjects will be dosed once every 12 weeks. However, repeated dosing at any dose level will not begin until the anticipated cumulative dose for that cohort has been equaled or exceeded in Part A and/or B of the study, and appropriate safety review of data from all preceding doses in prior subjects has taken place. All subjects randomized into Part A of the study will automatically continue into Part B unless dosing is halted at the individual or group level due to safety or other concerns.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

anti-PD-L1 monoclonal antibody IBC-Ab002 early Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Within each cohort subjects are randomized to either active investigational product or placebo in a ratio 3:1

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Intervention Type OTHER

Normal Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IBC-Ab002

An anti-PD-L1 monoclonal antibody

Intervention Type BIOLOGICAL

Placebo

Normal Saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of early Alzheimer's disease based on the National Institute on Aging and Alzheimer's Association) (NIA-AA Research Framework criteria, regardless of apolipoprotein E (APOE) gene status.
2. Able to speak, read and write the local language fluently.
3. With respect to symptomatic treatment for Alzheimer's disease, subjects should either be not treated with any approved treatments for AD or stabilized on approved medication(s) other than anti-Ab antibodies for the treatment of AD for at least 3 months prior to Baseline.
4. Subject has a study partner who spends at least 10 hours/week with the subject, and can attend all visits with the subject, report accurately on the subject's status, and ensure compliance with all study requirements
5. Subject and study partner must each independently be able to understand the study requirements and provide informed consent

Exclusion Criteria

1. Females who are not postmenopausal at Screening as defined by amenorrhea for at least 12 consecutive months or who have not been sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before Screening)
2. Other than Alzheimer's disease, any neurologic or medical disorder which may impair cognition.
3. Any contra-indication to undergo magnetic resonance imaging (MRI).
4. Severe vision or hearing impairment that would prevent the subject from performing psychometric tests or otherwise complying with requirements for study participation and activities.
5. History of certain neurological, psychiatric or medical conditions including autoimmune diseases.
6. Clinically significant laboratory or electrocardiogram (ECG) abnormalities
7. Presence of contraindication to lumbar puncture (LP) including taking anticoagulant or antiplatelet medications other than aspirin at a dose of ≤ 100 mg/day or clopidogrel.
8. Taking any of the following medications.

1. Immunosuppressant medications, including chronic systemic corticosteroids (chronic use of topical steroids is allowed)
2. Injected or infused antibody therapies, including but not limited to antibodies directed against tumor necrosis factor (TNF), anti-interleukin-6 (anti-IL-6), natalizumab, rituximab and similar agents
3. Aducanumab, (aducanumab-avwa) intravenous injection (brand name: Aduhelm™), or any other experimental or approved anti-amyloid antibody
4. Insulin
5. Anticoagulant or anti-platelet medications including warfarin, heparinoids and direct coagulation factor inhibitors (e.g. apixaban, dabigatran, rivaroxaban) within 90 days of the planned first dose of study drug; either aspirin at a dose of \< 100 mg/day or clopidogrel at a dose of 75 mg/day, but not both in combination is permitted
9. Participation in any other interventional clinical trial, or treatment with any investigational drug or investigational use of an approved therapy, within 30 days or 5 half-lives of such agent, whichever is longer, prior to the first Screening visit
10. Subject currently smokes more than 5 cigarettes or equivalent tobacco consumption daily
11. Regular nonmedical use of cannabis or cannabis products unless such products are documented by the manufacturer's label not to contain tetrahydrocannabinol or its derivatives or analogs
12. History of drug (including cannabis) or alcohol abuse within the last 5 years
13. Positive urine drug test for drugs of abuse at Screening. Subjects who test positive for benzodiazepines or opioids in urine drug testing need not be excluded if in the clinical opinion of the investigator, this is due to the subject taking prior/concomitant medications containing benzodiazepines or opioids for a medical condition and not due to drug abuse
14. Subjects who answer "yes" to Columbia Suicidality Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening
15. Unwillingness to comply with study requirements or history of noncompliance in prior clinical trials

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tommaso Croese, MD

Role: STUDY_DIRECTOR

Immunobrain Checkpoint

Catherine Mummery, MD

Role: PRINCIPAL_INVESTIGATOR

Dementia Research Centre, UCL, London

Review additional registry numbers or institutional identifiers associated with this trial.

1R01AG071810-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2021-006580-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PTCG-20-701033

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

U1111-1303-6922

Identifier Type: OTHER

Identifier Source: secondary_id

IBC-01-01

Identifier Type: -

Identifier Source: org_study_id

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Cohort 1

IBC-Ab002

Placebo

Cohort 2

IBC-Ab002

Placebo

Cohort 3

IBC-Ab002

Placebo

Cohort 4

IBC-Ab002

Placebo

Cohort 5

IBC-Ab002

Placebo

Interventions

IBC-Ab002

Placebo

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

National Institute on Aging (NIA)

Alzheimer's Association

Immunobrain Checkpoint

Responsible Party

Principal Investigators

Tommaso Croese, MD

Catherine Mummery, MD

Locations

Barzilai Medical Center

Rabin Medical Center

Sheba Medical Center

Tel-Aviv Sourasky Medical Center

Brain Research Center

University Hospital Southampton NHS Foundation Trust

RICE - Research Institute for the Care of Older People

King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)

Dementia Research Centre, National Hospital for Neurology and Neurosurgery

Sheffield teaching Hospitals NHS Trust

Countries

Other Identifiers

1R01AG071810-01

2021-006580-19

PTCG-20-701033

U1111-1303-6922

IBC-01-01